Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab for bone loss prevention in breast cancer (ENDEAVOR)
NCT03324932Phase 3Active, not recruiting
- Sponsor
- Kyoto Prefectural University of Medicine
- Start
- Sep 2017
- Primary completion
- Dec 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of denosumab in osteoporosis, sponsored by Kyoto Prefectural University of Medicine. Started Sep 2017; status: active, not recruiting.
02
Drugs
denosumab
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT03324932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03324932.